Dr. Jeff Weitz

Division of Hematology & Thromboembolism

Jeffrey Weitz

M.D. F.R.C.P.(C), F.A.C.P

Professor, Division of Hematology and Thromboembolism, Department of Medicine

Executive Director, Thrombosis & Atherosclerosis Research Institute

 

 

 

 

Biography

Dr. Weitz is Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute. Board Certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz focuses his clinical practice on patients with thrombotic disorders. His research spans the spectrum from basic studies in the biochemistry of blood coagulation and fibrinolysis to animal models of thrombosis and on to clinical trials of antithrombotic therapy. The breadth of his work is highlighted by his over 500 publications in journals as diverse as the Journal of Clinical Investigation, Journal of Biological Chemistry, Biochemistry, Circulation, Blood, Annals of Internal Medicine, New England Journal of Medicine and Lancet, and 60 book chapters. The recipient of numerous awards, Dr. Weitz is a Fellow of the American Heart Association, the Royal Society of Canada and the Canadian Academy of Health Sciences.

By focusing on the basic mechanisms by which anticoagulants (blood thinners) and thrombolytic agents (clot digesting drugs) work, Dr. Weitz has opened new avenues of investigation. His demonstration that thrombin bound to fibrin is resistant to inactivation by available anticoagulants stimulated the development of new drugs, some of which are already being used in clinical practice. Through other research, Dr. Weitz has provided an explanation for the puzzling clinical observation that the clot digesting drug, tissue-type plasminogen activator or t-PA, produces more bleeding than was originally anticipated. This work has paved the way for new drugs that may be safer than t-PA.

Dr. Weitz is involved in clinical trials examining optimal methods for prevention, diagnosis and treatment of clotting disorders. He also is an active participant in the education of medical students, residents, and postdoctoral fellows. In addition, he coordinates a graduate course in medical sciences and his laboratory is a fertile training ground for graduate students and postdoctoral fellows in medical sciences and bioengineering.

Selected Publications

  1. Weitz JI, Hudoba M, Massel D, et al. (1990) Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J.Clin.Invest. 86, 385-391.
  2. Weitz JI, Connolly SJ, Patel I, et al. (2010) Randomised, parallel-group, multicentre, multinational phase2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb.Haemost. 104, 633-641.
  3. Yau JW, Stafford AR, Liao H, et al. (2011) Mechanism of catheter thrombosis:  Comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood 118, 6667-6674.
  4. MacQuarrie JL, Stafford AR, Yau JW, et al. (2011) Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation. Blood 117, 4134-4141.
  5. Yau JW, Stafford AR, Liao P, et al. (2012) Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. Acta Biomater. 8, 4092-4100.
  6. Agnelli G, Buller HR, Cohen A, et al. (2013) Oral apixaban for the treatment of acute venous thromboembolism. N.Engl.J.Med. 369, 799-808.
  7. Agnelli G, Buller HR, Cohen A, et al. (2013) Apixaban for extended treatment of venous thromboembolism. N.Engl.J Med. 368, 699-708.
  8. Yau JW, Liao P, Fredenburgh JC, et al. (2014) Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 123, 2102-2107.
  9. Raskob GE, Angchaisuksiri P, Blanco AN, et al. (2014) Thrombosis: a major contributor to global disease burden. Arterioscler.Thromb.Vasc.Biol. 34, 2363-2371.
  10. Pollack CV, Jr, Reilly PA, Eikelboom J, et al. (2015) Idarucizumab for dabigatran reversal. N.Engl.J.Med. 373, 511-520.
  11. Buller HR, Bethune C, Bhanot S, et al. (2015) Factor XI antisense oligonucleotide for prevention of venous thrombosis. N.Engl.J Med. 372, 232-240.
  12. Vu TT, Zhou J, Leslie BA, et al. (2015) Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein. Blood 125, 2712-2719.
  13. Pollack CV, Jr, Reilly PA, Van Ryn J, et al. (2017) Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N.Engl.J Med. 377, 431-441.
  14. Weitz JI, Lensing AW, Prins MH, et al. (2017) Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N.Engl.J.Med. 376, 1211-1222.